Mitchell L. Jones

Mitchell L. Jones has an extensive background in biopharmaceuticals, particularly in clinical development and corporate strategy. Mitchell L. has held leadership roles at companies like Palisade Bio, Catapult Solutions Group, Chemomab Therapeutics, Finch Therapeutics, Biora Therapeutics, Interface Therapeutics Inc., and Micropharma. Throughout their career, Mitchell has spearheaded various initiatives, ranging from developing novel therapies for inflammatory bowel disease to securing funding for the development of oral biotherapeutics targeting metabolic diseases. Mitchell L.'sexpertise includes strategic planning, clinical program development, and identifying key partnerships for the advancement of therapeutic programs.

Mitchell L. Jones completed their Bachelor's degree in Human Physiology at McGill University. Mitchell L. then went on to obtain a Master's degree in Bioengineering and Biomedical Engineering from the same institution. Following this, they pursued a Medical Doctorate (M.D.) in Clinical Medicine at McGill University, which they completed in 2007. Finally, Mitchell earned their Ph.D. in Bioengineering and Biomedical Engineering from McGill University in 2011. Mitchell L. attended Markham District High School for their high school education.